ABI-DARGHAM, A., LAURELLE, M. (2005). Mechanisms of action of second generation antipsychotic drugs in schizophrenia: insights from brain imaging studies. Eur.
Psychiatry, 20: 15-27. Erişim: www.pubmed.com. Erişim tarihi: 04.12.2007.
AKDEDE, B.B., ALPTEKİN. K. (2004). Şizofrenide bilişsel işlev bozuklukları ve antipsikotik tedavi. Klinik Psikofarmakoloji Bülteni, 14(3): 178-184. Erişim:
www.psikofarmakoloji.org/pdf/14_3_8.pdf . Erişim tarihi: 16.11.2007.
ANDREASEN, N.C., REZAI, K., ALLIGER, R., SWAYZE II, V.W., FLAUM, M., KIRCHNER, P., COHEN, G., O’LEARY, D.S. (1992). Hypofrontality in neuroleptic-naive patients and in patients with chronic schizophrenia. Arch. Gen.
Psychiatry, 49: 943-958. Erişim: www.pubmed.com. Erişim tarihi: 04.12.2007.
ARAVAGIRI, M., MARDER, S.R., van PUTTEN, T., MIDHA, K.K. (1993). Determination of risperidone in plasma by high-performance liquid chromatography with electrochemical detection: application to therapeutic drug monitoring in schizophrenic patients. J. Pharm. Sci., 82(5): 447-449.
ARAVAGIRI, M., MARDER, S.R., WIRSHING, D., WIRSHING, W.C. (1998). Plasma concentrations of risperidone and its 9-hydroxy metabolite and their relationship to dose in schizophrenic patients: simultaneous determination by a high performance liquid chromatography with electrochemical detection. Pharmacopsychiatry, 31(3):102-109.
ARAVAGIRI, M., MARDER, S.R. (2000). Simultaneous determination of risperidone end 9-hydroxyrisperidone in plasma by liquid chromatography/electrospray tandem mass spectrometry. J. Mass. Spectrom., 35(6): 718-724.
AVENOSO, A., FACCIOLA, G., SALEMI, M., SPINA, E. (2000). Determination of risperidone and its major metabolite 9-hydroxyrisperidone in human plasma by reversed-phase liquid chromatography with ultraviolet detection. J. Chromatogr.
B. Biomed. Sci. Appl., 746(2): 173-181.
BEN-SHACHAR, D., LAIFENFELD, D. (2004). Mitochondria, synaptic plasticity, and schizophrenia. International Review of Neurobiology, 59: 273-296. Erişim:
www.sciencedirect.com. Erişim tarihi: 04.12.2007.
BHATT, J., SUBBAIAH, G., SINGH, S. (2006). Liquid chromatography/tandem mass spectrometry method for simultaneous determination of risperidone and its active metabolite 9-hydroxyrisperidone in human plasma. Rapid Commun. Mass Spectrom., 20(14): 2109-2114.
BIGLIANI, V., MULLIGAN, R.S., ACTON, P.D., OHLSEN, R.I., PIKE, V.W., ELL, P.J., GACINOVIC, S., KERWIN, R.W., PILOWSKY, L.S. (2000). Striatal and temporal cortical D2/D3 receptor occupancy by olanzapine and sertindole in vivo: a [123I]epidepride single photon emission tomography (SPET) study.
Psychopharmacology (Berl), 150: 132-140. Erişim: www.pubmed.com. Erişim tarihi: 04.12.2007.
BRESSAN, R.A., ERLANDSSON, K., JONES, H.M., MULLIGAN, R.S., ELL, P.J., PILOWSKY, L.S. (2003). Optimizing limbic selective D2/D3 receptor occupancy by risperidone: a [123I]-epidepride SPET study. J. Clin. Psychopharmacol., 23: 5-14. Erişim: www.pubmed.com. Erişim tarihi: 04.12.2007.
BRUCKE, T., ROTH, J., PODREKA, I., STROBL, R., WENGER, S., ASENBAUM, S.
(1992). Striatal dopamine D2-receptor blockade by typical and atypical neuroleptics. Lancet, 339(8791): 497.
BUBBER, P., TANG, J., HAROUTUNIAN, V., XU, H., DAVIS, K.L., BLASS, J.P. (2004).
Mitochondrial enzymes in schizophrenia. Journal of Molecular Neuroscince, 24:
315-321. Erişim: www.pubmed.com. Erişim tarihi: 04.12.2007.
BUDAVARI, S. (1996). The Merck Index, Twelfth Edition Ed.: Budavari, S., USA: Merck Research Lab., s: 1417.
BYERLY, M.J., NAKONEZNY, P.A, BETTCHER, B.M., CARMODY, T., FISHER, R., RUSH, A.J. (2006). Sexual dysfunction associated with second-generation antipsychotics in outpatients with schizophrenia or schizoaffective dsorder: An empirical evaluation of olanzapine, risperidone, and quetiapine. Schizophrenia Research, 86: 244-250. Erişim: www.sciencedirect.com. Erişim tarihi: 16.11.2007.
CASEY, D.E. (1996). Side effect profile of new antipsychotic agents. J. Clin. Psychiatry, 57(suppl. 11): 40-45. Erişim: www.pubmed.com. Erişim tarihi: 04.12.2007.
CATAFAU, A.M., CORRIPIO, I., PEREZ, V., MARTIN, J.C., SCHOTTE, A., CARRIO, I., ALVAREZ, E. (2006). Dopamine D2 receptor occupancy by risperidone:
Implications for the timing and magnitude of clinical response. Psychiatry Research: Neuroimaging, 148: 175-183. Erişim: www.sciencedirect.com. Erişim tarihi: 16.11.2007.
CHEW, M.L., MULSANT, B.H., POLLOCK, B.G., LEHMAN, M.E., GREENSPAN, A., KIRSHNER, A., BIES, R.R., KAPUR, S., GHARABAWI, G. (2006). A model of anticholinergic activity of atypical antipsychotic medications. Schizophrenia Research, 88: 63-72. Erişim: www.sciencedirect.com. Erişim tarihi: 16.11.2007.
DUAN, X.T., CHEN, X.Y., ZHANG, Y.F., ZHONG, D.F. (2006). Determination of risperidone in human plasma by liquid chromatography-tandem mass spectrometry. Yao Xue Xue Bao, 41(7): 684-688.
DUPLAY, D. (2005). Physicians’ Desk Referance, 59 Addition. Ed: Duplay, D., Montvale:
Thomson PDR, s: 1742-1747.
EL-SHERIF, Z.A., EL-ZEANY, B., EL-HOUSSNI, O.M. (2005). High performance liquid chromatographic and thin layer densitometric methods for the determination of risperidone in the presence of its degradation products in bulk powder and in tablets.
J. Pharm. Biomed. Anal., 36(5): 975-981.
EUROPEAN PHARMACOPEIA (01/2006), 5.3 Supplement, 5th Edition. s: 3602-3604.
FLARAKOS, J., LUO, W., AMAN, M., SVINAROV, D., GERBER, N., VOUROS, P.
(2004). Quantification of risperidone and 9-hydroxyrisperidone in plasma and saliva from adult and pediatric patients by liquid chromatography-mass spectrometry. J.
Chromatogr. A., 1026(1-2):175-83.
FRAHNERT, C., RAO, M.L., GRASMADER, K. (2003). Analysis of eighteen antidepressants, four atypical antipsychotics and active metabolites in serum by liquid chromatography: a simple tool for therapeutic drug monitoring. J.
Chromatogr. B. Analyt. Technol. Biomed. Life Sci., 794(1): 35-47.
GEFVERT, O., ERIKSSON,B., PERSSON, P., HELLDIN, L., BJORNER, A., MANNAERT, E., REMMERIE, B., EERDEKENS, M., NYBERG, S. (2005).
Pharmacocinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta) in patients with schizophrenia. Int. J. Neuropsychopharmacol., 8:
27-36. Erişim: www.pubmed.com. Erişim tarihi: 04.12.2007.
GOFF, D.C., TSAI, G., BEAL, M.F., COYLE, J.T. (1995). Tardive dyskinesia and substrates of energy metabolism in CSF. American Journal ou Psychiatry, 152:
1730-1736. Erişim: www.pubmed.com. Erişim tarihi: 04.12.2007.
GÜNDÜZ, T. (1988). Enstrümantal Analiz Kitabı. Ankara: Gazi Büro Kitabevi.
KAPUR, S., ZIPURSKY, R.B., REMINGTON, G. (1999). Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am. J. Psychiatry, 156: 286-293. Erişim:
www.pubmed.com. Erişim tarihi: 04.12.2007.
KATO, T., MONJI, A., HASHIOKA, S., KANBA, S. (2007). Rrisperidone significantly inhibits interferone-γ-induced microglial activation in vitro. Schizophrenia Reserch, 92: 108-105. Erişim: www.sciencedirect.com. Erişim tarihi: 16.11.2007.
KAYAALP, S.O. (1995). Nöroleptik ilaçlar. Tıbbi Farmakoloji Gözden Geçirme Kitabı, Ankara: Hacettepe-Taş Kitapçılık Ltd. Şti. s.: 255-257.
KESSLER, R., ANSARI, S., LI, R., DAWANT, B., LEE, M., MELTZER, H. (2002).
Ocupancy of striatal and extrastriatal dopamine D2 receptors by atypical antipsychotic drugs. J. Nucl. Med., 43 (Suppl, 15P).
KINON, B.J., JONNA, A., LIU-SEIFERT, H., MAGUIRE, G.A. (2006). Improvement in hyperprolactinamia and reproductive comorbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapine.
Psychoneuroendocrinology, 31: 577-588. Erişim: www.sciencedirect.com. Erişim tarihi: 16.11.2007.
KIRCHHERR, H., KUHN-VELTEN, W.N. (2006). Quantitive determination of forty-eight antidepressants and antipsychotics in human serum by HPLC tandem mass spectrometry: A multi-level, single sample approach. J Chromatogr B Analyt Technol. Biomed. Life Sci., Jun 22.
Le MOING, J.P., EDOUARD, S., LEVRON, J.C. (1993). Determination of risperidone and 9-hydroxyrisperidone in human plasma by high-performance liquid chromatography with electrochemical detection. J. Chromatogr., 614(2): 333-339.
LEVILLAIN, P., FOMPEYDIE, D. (1986). Spectrophotometric derivee. Analysis.,14: 1.
LIEBERMAN, J.A. (1999). Is schizophrenia a neurodegenerative disorder? A clinical and neurobiological perspective. Biol. Psychiatry, 46: 729–739. Erişim:
www.sciencedirect.com Erişim tarihi: 04.12.2007.
LIEBERMAN, J.A., TOLLEFSON, G.D., CHARLES, C., ZIPURSKY, R., SHARMA, T., KAHN, R.S., KEEFE, R.S., GREEN, A.I., GUR, R.E., McEVOY, J., PERKİNS, D., HAMER, R.M., GU, H., TOHEN, M. (2005). Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch. Gen. Psychiatry, 62: 361-370.
Erişim: www.pubmed.com. Erişim tarihi: 04.12.2007.
LLERENA, A., BERECZ, R., DORADO, P., DE LA GARZA, C.S., NORBERTO, M.J., CACERES, M., GUTIERREZ, J.R. (2003). Determination of risperidone and 9-hydroxyrisperidone in human plasma by liquid chromatography: application to the evaluation of CYP2D6 drug interactions. J. Chromatogr. B. Analyt. Technol.
Biomed. Life Sci., 783(1): 213-219.
MAURER, H.H. (2005). Advances in analytical toxicology: the current role of liquid chromatography-mass spectrometry in drug quantification in blood and oral fluid.
Anal. Bioanal. Chem., 381(1):110-118.
MEDORI, A., MANNAERT, E., GRNDER, G. (2006). Plasma antipsychotic concentration and receptor occupancy, with special focus on risperidone long acting injectable.
European Neuropsychopharmacology, 16: 233-240. Erişim:
www.sciencedirect.com. Erişim tarihi: 16.11.2007.
MEISENZAHL, E.M., FROLD, T., ZETSCHE, T., LEISINGER, G., MAAG, K., HEGERL, U., HAHN, K., MOYYER, H.J. (2002). Investigation of possible diencephalic pathology in schizophrenia. Psychiatry Research: Neuroimaging, 115: 127-135.
Erişim: www.sciencedirect.com. Erişim tarihi: 04.12.2007.
MELTZER, H.Y. (1995). The concept of antipsychotic drugs; Advences in the Neurobiology of Schizophrenia, Ed.: den Boer, J.A., Westenberg, H.G.M., van Prag, H.M., London: Wiley & Sons, s.: 297-308.
METE, L., ÜNSAL, P.Ç. (2004). Yeni kuşak antipsikotiklerin metabolik yan etkileri. Klinik Psikofarmakoloji Bülteni, 14(3): 168-177. Erişim:
www.psikofarmakoloji.org./tr/ozet.asp?ID=202&Volume=14&Issue=3&year=200 4 . Erişim tarihi: 16.11.2007.
MODDY, D.E., LAYCOCK, J.D., HUANG, W., FOLTZ, R.L. (2004). A high-performance liquid chromatographic-atmospheric pressure chemical ionization-tandem mass spectrometric method for determination of risperidone and 9-hydroxyrisperidone in human plasma. J. Anal. Toxicol., 28(6): 494-497.
MURPHY, B.P., CHUNG, Y.-C., PARK, T.-W., McGORRY, P.D. (2006). Pharmalogical treatment of primary negative smptoms in schizophrenia: A systematic rewiev.
Schizophrenia Reserch, 88: 5-25. Erişim: www.sciencedirect.com. Erişim tarihi:
16.11.2007.
NAGASAKI, T., OHKUBO, T., SUGAWARA, K., YAUSI, N., FURUKORI, H., KANEKO, S. (1999). Determination of risperidone and 9-hydroxyrisperidone in human plasma by high-performance liquid chromatography: application to therapeutic drug monitoring in Japanese patients with schizophrenia. J. Pharm.
Biomed. Anal., 19(3-4): 595-601.
NIBUYA, M., KANBA, S., SEKIA, U., SUZUKI, E., MATSUO, Y., KINOSHITA, N., SHINTANI, F., YAGI, G., ASAI, M. (1995). Shizophrenic patients with deficit syndrome have higher plasma homovalinic acid concentrations and ventricular enlargement. Biol. Psychiatry, 38: 50-56. Erişim: www.sciencedirect.com.Erişim tarihi: 04.12.2007.
OLESEN, O.V., LINET, K. (1997). Simplified high performance liquid chromatographic method for determination of risperidone and 9-hydroxyrisperidone in serum from patients comedicated with other psychotropic drugs. J. Chromatogr. B. Biomed.
Sci. Appl., 698(1-2): 209-216.
ONUR, F., YÜCESOY, C. (1983). Türev spektrofotometrisi. Fabad J. Pharm. Sci.,13: 462.
ÖZALMETE, E.Ö. (2006). Şizofrine hastalarının tedavisinde antipsikotik polifarmasi uygulamasının değerlendirilmesi. Uzmanlık Tezi, Sağlık bakanlığı Bakırköy Prof.
Dr. Mahzar Osman Ruh Sağlığı ve Sinir Hastalıkları Eğitim ve Araştırma Hastanesi Baştabipliği, 4. Psikiyatri Klinik Şefliği. Erişim:
www.istanbulsaglik.gov.tr/w/tez/tez_psikiyatri.asp . Erişim tarihi: 16.11.2007.
PILLAI, A., PARIKH, V., TERRY Jr, A.V., MAHADIK, S.P. (2007). Long-term antipsychotic treatments and crossover studies in rats: Differential effects of typical and atypical agents on the expression of antioxidant enzymes and membrane lipid peroxidation in rat brain. Journal of Psychiatric Research, 41:
372-386. Erişim: www.sciencedirect.com. Erişim tarihi: 16.11.2007.
PILOWSKY, L.S., MULLIGAN, R.S., ACTON, P.D. ELL, P.J., COSTA, D.C., KERWIN, R.W. (1997). Limbic selectivity of clozapine. Lancet, 350: 490-491.
RAO, M.L., MOLLER, H.J. (1994). Biochemical findings of negative symtoms in schizophrenia and their putative relevanca to pharmacologic treatment.
Neuropsychobiology, 30: 160-172. Erişim: www.pubmed.com. Erişim tarihi:
04.12.2007.
RAGGI, M.A., BUGAMELLI, F., SABBONI, C., SARACINO, M.A., PETIO, C. (2005).
HPLC-DAD determination of plasma levels of the antipsychotic risperidone and its main metabolite for toxicological purposes. J. Sep. Sci., 28(3): 245-250.
REMMERIE, B.M., SIPS, L.L., de VRIES, R., de JONG, J., SCHOTHUIS, A.M., HOOIJSCHUUR, E.W., van de MERBEL, N.C. (2003). Validated method for the determination of risperidone and 9-hydroxyrisperidone in human plasma by liquid chromatography-tandem mass spectrometry. J. Chromatogr. B. Analyt. Technol.
Biomed. Life Sci., 783(2): 461-472.
ROTH, B.L., TANDRA, S., BURGESS, L.H. ve ark. (1995). D4 dopamine receptor binding affinity does not distinguish between typical ve atypical antipsychotic drugs.
Psychopharmacology, 120: 365-368.
SARBY, S.M., ABDEL-HAY, M.H., BARARY, M.H., BELAL, T.S. (2000). Sensitive spectrofluorimetric and spectrophotometric methods for the determination of thonzylamine hydrochloride in pharmaceutical preparations based on coupling with dimethylbarbituric acid in presence of dicyclohexylcarbodiimide. J. Pharm.
Biomed. Anal., 22: 257-264.
SCHATZ, D.S., SARIA, A. (2000). Simultaneous determination of paroxetine, risperidone and 9-hydroxyrisperidone in human plasma by high-performance liquid chromatography with coulometric detection. Pharmacology, 60(1): 51-56.
SEEMAN, P., LEE, T., CHAU-WONG, M., WONG, K. (1976). Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature, 261: 717-719.
SEEMAN, P. (2002). Atypical antipsychotics: mechanism of action. Can. J. Psychiatry, 47:
27-38. Erişim: www.pubmed.com. Erişim tarihi: 04.12.2007.
SKOOG, D.A., HOLLER, F.J., NIEMAN, T.A. (1997) Principles of Instrumental Analysis, Fifth Edition. Ed: Kılıç, E., Köseoğlu, F., Yılmaz, H. Bilim Yayıncılık, Ankara.
SKOOG, D.A., WEST, D.M., HOLLER, F.J. (1996). High-performance liquid chromatography. Fundamentals of Analytical Chemistry, Seventh Edition,Saunders College Publishing, s.:701-724.
SONG, Z., WANG, C. (2004). Sensitive chemiluminescence assay for risperidone in pharmaceutical preparations. J. Pharm. Biomed. Anal., 36(3):491-494.
SOYKAN, A. (2000). Atipik antipsikotiklere genel bakış. Klinik Psikiyatri, 1: 13-21. Erişim:
www.klinikpsikiyatri.org/pdf/4/3/ek11/13.pdf . Erişim tarihi: 16.11.2007.
STAHL, M.S. (1996). Essential psychopharmacology. United Kingdom: Cambridge University Press, s.: 222-289.
SWEETMAN, S.C. (2007-a). Anxiolytic sedatives hypnotics and antipsychotics: Martindale The Complete Drug Reference 35th Edition Volume:1, Ed: Sweetman, S.C.
London: Pharmaceutical Pres, s: 851-857.
SWEETMAN, S.C. (2007-b). Risperidone: Martindale The Complete Drug Reference 35th Edition Volume:1, Ed: Sweetman, S.C. London: Pharmaceutical Press, s: 921-923
TITIER, K., BOUCHET, S., PEHOURCQ, F., MOORE, N., MOLIMARD, M. (2003).
High-performance liquid chromatographic method with diyote array detection to identify and quantify atypical antipsychotics and haloperidol in plasma after overdose. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 788(1): 179-85.
TUĞLULAR, I. (2000). Psikiyatrik bozuklukların tedavisinde kullanılan ilaçlar I: psikoz ve anksiyete tedavisinde kullanılan ilaçlar. Türk Farmakoloji Derneği, Farmakoloji Ders Kitabı, Ed.: Bökesoy, T.A., Çakıcı, İ., Melli, M. Ankara: Gazi Kitabevi, s.: 296-305.
WHATLEY, S.A., CURTI, D., DAS GUPTA, F., FERRIER, I.N., JONES, S., TAYLOR, C.
(1998). Superoxide, neuroleptics and the ubiquinones and cytochrome b5 reductases in brain and lymphocytes from normals and schizophrenic patients.
Molecular Psychiatry, 3: 227-237. Erişim: www.pubmed.com. Erişim tarihi:
04.12.2007.
WOESTENBORGHS, R., LORREYNE, W., van ROMPAEY, F., HEYKANTS, J. (1992).
Determination of risperidone and 9-hydroxyrisperidone in plasma, urine and animal tissues by high-performance liquid chromatography. J. Chromatogr., 583(2): 223-230.
YAĞCIOĞLU, E.A. (2007). Aitipik antipsikotik ilaçların etki mekanizmaları: Şizofreni tedavisinde “atipiklik” bir üstünlük mü? Türk Psikiyatri Dergisi, 18(3): 1-11.
Erişim:www.turkpsikiyatri.com/Data/UnpublishedArticles/antipsikotikilacların.pd f . Erişim tarihi: 16.11.2007.
YILDIZ, A., GENÇ, O. (1993). Ultraviyole ve görünür bölge moleküler absorbsiyon spektroskopisi. Enstrümantal Analiz, Ankara: Hacettepe Taş Kitapçılık, 43.
Ankara
YÜKSEL, N. (2000). Dirençli şizofreni tedavisi. Şizofreni Dizisi, 1: 67-71. Erişim:
www.cty.com.tr/pdf/25/3/64.pdf . Erişim tarihi: 16.11.2007.
ZHOU, Z., LI, K., XIE, Z., CHENG, Z., PENG, W., WANG, F., ZHU, R., LI, H. (2004).
Simultaneous determination of clozapine, olanzapin, risperidone and quetiapine in plasma by high-performance liquid chromatography-electrospray ionization mass spectrometry. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci., 802(2):
257-262.
XIAO, H., YANG, J., ZHANG, S., ZHANG, X. (1999). Determination of risperidone and 9-hydroxyrisperidone in plasma by high performance liquid chromatography. Se Pu, 17(4): 395-396.